相关临床试验
222
14 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
10
4.5%
已完成
98
44.1%
尚未招募
4
1.8%
招募中
27
12.2%
暂停
1
0.5%
终止
69
31.1%
撤回
13
5.9%
暂无批准数据
- Researchers at Vanderbilt-Ingram Cancer Center demonstrated that liquid biopsies using repeated blood sampling can effectively predict patient response to immunotherapy in high-risk, early-stage breast cancer. - The study analyzed 546 blood samples from 160 patients with HER2-negative stage 2 and 3 breast cancers, using RNA sequencing to study T cell activation gene expression patterns. - Molecular signals in blood samples successfully predicted patient response to the immunotherapy drug Pembrolizumab, offering a minimally invasive alternative to traditional tissue biopsies. - The findings suggest this approach could guide immunotherapy decisions and enable personalized treatment strategies across multiple cancer types.
- Cleveland Clinic researchers presented final Phase 1 results for an investigational vaccine targeting triple-negative breast cancer, showing a 74% immune response rate across 35 participants. - The vaccine targets α-lactalbumin protein found in 70% of triple-negative breast cancers and was deemed safe with only mild injection site reactions reported. - A Phase 2 efficacy trial is planned for late 2025 to evaluate whether the immune response translates into reduced recurrence risk for this aggressive cancer type. - Triple-negative breast cancer represents 10-15% of cases but causes disproportionate deaths, particularly affecting Black women and BRCA1 mutation carriers.
- Real-world evidence complements randomized clinical trials by addressing treatment questions for colorectal cancer patients who are ineligible or underrepresented in clinical studies. - Recent data shows KRAS G12C-mutated metastatic colorectal cancer patients experience shorter survival with median overall survival of 18.2 months compared to 19.1 months for other KRAS mutations. - Treatment sequencing remains unclear between approved agents like regorafenib and TAS-102, with real-world studies showing comparable efficacy but different toxicity profiles. - Clinical experts emphasize the need for more inclusive trial designs to better represent diverse patient populations including older adults and those with multiple comorbidities.
- A real-world analysis of 12,318 patients with metastatic colorectal cancer revealed that KRAS G12C mutations, present in 3% of cases, were associated with numerically shorter overall survival and progression-free survival compared to non-G12C mutations. - Patients with KRAS G12C-mutant mCRC had a median overall survival of 18.2 months versus 19.1 months for those with KRAS non-G12C mutations when treated with standard first-line chemotherapy regimens. - The findings suggest that KRAS G12C mutations may serve as a negative prognostic factor, potentially influencing treatment decisions and supporting earlier consideration of targeted therapies or clinical trial participation. - Survival outcomes were comparable across different first-line chemotherapy backbones within the KRAS G12C-mutant cohort, indicating that the mutation's prognostic impact may be independent of specific chemotherapy regimens.
- Vanderbilt researchers developed albumin-hitchhiking nanobodies that extend circulation time from 5 minutes to 55 hours and achieve 11% injected dose per gram tumor accumulation. - The nanobody-STING agonist conjugates demonstrated complete tumor elimination in 100% of breast cancer models and significant efficacy against melanoma metastases. - A bivalent nanobody targeting both albumin and PD-L1 showed superior therapeutic outcomes, generating immunological memory that prevented tumor recurrence in 89% of treated mice. - The platform activated CD8+ T cells and NK cells as primary antitumor effectors while stimulating antigen-specific memory responses against tumor-associated antigens.
- High levels of tumor-infiltrating lymphocytes (TILs) strongly correlate with improved survival in triple-negative breast cancer patients, with 94% 5-year survival rates observed in patients with TIL levels ≥50%. - Studies demonstrate that TNBC tumors with elevated TIL levels respond favorably to immunotherapy, with pembrolizumab showing superior outcomes in high-TIL patients compared to chemotherapy. - Beyond TILs, emerging biomarkers including MHC-II expression, tumor mutational burden, and B-cell markers show potential for optimizing immunotherapy patient selection in TNBC treatment.
- Eight-year data from CheckMate 214 show nivolumab plus ipilimumab demonstrates long-term efficacy in intermediate- and poor-risk advanced renal cell carcinoma (RCC). - In favorable-risk patients, nivolumab plus ipilimumab shows a hazard ratio of 0.82, surpassing historical IO-TKI trial results, suggesting its viability in this group. - IO-TKI combinations are beneficial for patients needing rapid response due to high disease burden, while IO-IO combinations offer potential for long-term disease control. - Ongoing trials are exploring novel targets like HIF2α inhibitors to overcome resistance to immune checkpoint inhibition in RCC management.
• Despite FDA approval of cetuximab plus encorafenib for BRAF V600E-mutated mCRC, significant challenges remain in treating patients who progress after BRAF inhibitor therapy. • The recent approval of adagrasib with cetuximab for KRAS G12C-mutated mCRC marks progress, but treatment options for other KRAS mutations remain limited, spurring interest in pan-RAS inhibitors. • Refractory mCRC patients without actionable mutations face limited treatment options, emphasizing the crucial role of clinical trials in advancing therapeutic development.
